Our Standard on clinical trial data transparency


Rationale

With respect to the principles set forth by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Pharmaceutical Research and Manufacturers of America (PhRMA), the Declaration of Helsinki and applicable laws and regulations (including requirements as defined by the Clinical Trials Regulation (EC) No 536/2014), we will inform the public about the designs and results of our clinical trials in a timely and balanced manner, regardless of the outcome.

We welcome the efforts to make in-depth information on clinical trials available to the public. Access to detailed information on clinical trials, irrespective of their outcome, can significantly improve the positive impact of clinical studies on the progress of medical research and development. Hence, the new transparency requirements in clinical research will primarily serve patients’ well-being and advance public health.

In accordance with current laws and regulations, we take great precautions to ensure the privacy of participants in our clinical trials. We also protect intellectual property, keep contract rights as well as current national practices in patent law.

Our company is thoughtfully integrating our commitment to transparency and disclosure into our clinical development opportunities in the following ways:

US/NPR/0517/0230(1)a(1)d   

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement